Express Pharma
NOVEMBER 21, 2023
It helps to enhance the immune function of cancer patients and prevent the side effects of neutropenia caused by chemotherapy. Ryzneuta is a novel long-acting Granulocyte colonystimulating factor (G-CSF), which can stimulate the proliferation, differentiation, and release of neutrophil precursors.
pharmaphorum
JANUARY 26, 2022
It covers three phase 3 trials involving subjects with myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML), as well as ‘unfit’ AML patients who are unable to be treated with intensive treatment like high-dose chemotherapy.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
NOVEMBER 23, 2022
Libtayo is also indicated for treating progression of the disease on or following platinum-based chemotherapy. The trial enrolled 608 subjects in 14 countries, regardless of their PD-L1 expression status or histology and assessed Libtayo versus a chemotherapy of investigator's choice.
LifeProNow
APRIL 19, 2023
The product is intended for use in adults and pediatric patients 12 years and older with blood cancers planned for umbilical cord blood transplantation following a myeloablative conditioning regimen (treatment such as radiation or chemotherapy). director of the FDA’s Center for Biologics Evaluation and Research.
European Pharmaceutical Review
NOVEMBER 24, 2022
s Libtayo ® (cemiplimab) for adults with recurrent or metastatic cervical cancer and disease progression while on or after platinum-based chemotherapy. “Libtayo ® was the first programmed cell death protein (PD)-1 inhibitor to demonstrate significant improvements in survival compared to chemotherapy in a Phase III trial.
The Thyroid Pharmacist
SEPTEMBER 1, 2023
They include anesthetics, antacids, anti-anxiety medications, antibiotics, antidepressants, antifungals, cholesterol-lowering medications, anti-malarial medications, chemotherapy, appetite suppressants, arthritis medications, psychotropics, and steroids. Who is Likely to Have an Adverse Reaction to Fluoride, and What are the Symptoms?
LifeProNow
APRIL 19, 2023
The safety of immunization with live viral vaccines during or after ABECMA treatment has not been studied. Vaccination with live virus vaccines is not recommended for at least 6 weeks prior to the start of lymphodepleting chemotherapy, during ABECMA treatment, and until immune recovery following treatment with ABECMA.
Expert insights. Personalized for you.
87 
Let's personalize your content